Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LGVN - Longeveron Inc - Ordinary Shares - Class A


IEX Last Trade
2.045
-0.045   -2.200%

Share volume: 362,317
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$2.09
-0.05
-2.15%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
6%
Profitability 0%
Dept financing 11%
Liquidity 41%
Performance 2%
Company vs Stock growth
vs
Performance
5 Days
-20.62%
1 Month
-37.61%
3 Months
87.16%
6 Months
-62.52%
1 Year
-91.64%
2 Year
-96.07%
Key data
Stock price
$2.04
P/E Ratio 
-0.94
DAY RANGE
N/A - N/A
EPS 
-$8.27
52 WEEK RANGE
$0.77 - $28.60
52 WEEK CHANGE
-$0.92
MARKET CAP 
26.266 M
YIELD 
N/A
SHARES OUTSTANDING 
12.875 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/08/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$862,563
AVERAGE 30 VOLUME 
$884,111
Company detail
CEO:
Region: US
Website: longeveron.com
Employees: 26
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome

Recent news